Therapeutic use of selective pde10 inhibitors
CA 2484600 A1 · Owner: Pfizer Products Inc. · Inventors: Menniti, Frank Samuel; Schmidt, Christopher Joseph; Lebel, Lorraine Ann
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a method for treating certain neurologic and psychiatric disorders in mammals, including humans comprising administration , of a selective PDE10 inhibitor. In particular the invention relates to , treatment of mood movement, and anxiety disorders; psychosis; drug for , example alcohol, addiction; disorders having as a symptom deficient cognition; and neurodegenerative disorders and conditions. The invention furthermore provides the use of papaverine as a selective inhibitor of PDE10. The invention also provides assays for identifying chemical compounds that have activity as selective PDE10 inhibitors.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 22, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 22, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 22, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.